SCHEMBL1225973

SCHEMBL1225973

ClC(/C=C/c1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.52
MAOB P27338 2/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 2/20 0.38
NFE2L2 Q16236 1/20 0.38
CYP19A1 P11511 1/20 0.38
MAOA P21397 1/20 0.38
TRPA1 O75762 1/20 0.38
ALOX5 P09917 1/20 0.38
PAM P19021 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
MAPT P10636 2/20 0.37
RECQL P46063 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HDAC3 O15379 1/20 0.37
TNKS O95271 1/20 0.37
HDAC4 P56524 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27906876 1.00 CYP1A2 (0.52) CYP1A2MAOBTSHRALDH1A1LMNA
SCHEMBL7737180 0.79 CYP1A2 (0.53) CYP1A2MAOBTSHRALDH1A1LMNA
SCHEMBL3834342 0.79 CYP1A2 (0.53) CYP1A2MAOBTSHRALDH1A1LMNA
SCHEMBL8754870 0.78 CYP1A2 (0.48) CYP1A2MAOBTSHRALDH1A1LMNA
SCHEMBL5455161 0.78 MAOB (0.50) CYP1A2MAOBALDH1A1LMNAMAPK1
SCHEMBL148999 0.78 MAOB (0.50) CYP1A2MAOBALDH1A1LMNAMAPK1
SCHEMBL477645 0.77 CYP1A2 (0.57) CYP1A2MAOBALDH1A1LMNATRPA1
SCHEMBL477467 0.77 CYP1A2 (0.57) CYP1A2MAOBALDH1A1LMNATRPA1
SCHEMBL477646 0.77 CYP1A2 (0.57) CYP1A2MAOBALDH1A1LMNATRPA1
SCHEMBL477469 0.77 CYP1A2 (0.57) CYP1A2MAOBALDH1A1LMNATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459727-A2 BIOCATALYST FOR CATALYTIC HYDROAMINATION BASF SE (DE) 2012-06-06 EP disclosed
US-20120123155-A1 BIOCATALYST FOR CATALYTIC HYDROAMINATION BASF SE (DE) 2012-05-17 US disclosed
WO-2011012632-A2 BIOCATALYST FOR CATALYTIC HYDROAMINATION BASF SE (DE) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123155-A1 BIOCATALYST FOR CATALYTIC HYDROAMINATION HDHD5, PAH, GRHPR CYP1A2 874/4885MAOB 501/4885TSHR 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.